• MDinteractive is an approved CMS Qualified Registry for
    2020 and 2021.

  • Did you miss our Primary Care First Webinar on reporting the Advance Care Planning measure?
    Click here to watch it now!

  • CMS Publishes 2021 Final Rule. What will it mean for your practice?
    Check out our highlights blog here.

2020 MIPS IA_PSPA_27: Invasive Procedure or Surgery Anticoagulation Medication Management

Activity ID

IA_PSPA_27

Activity Weighting

Medium

Subcategory Name

Patient Safety and Practice Assessment

Activity Description

For an anticoagulated patient undergoing a planned invasive procedure for which interruption in anticoagulation is anticipated, including patients taking vitamin K antagonists (warfarin), target specific oral anticoagulants (such as apixaban, dabigatran, and rivaroxaban), and heparins/low molecular weight heparins, documentation, including through the use of electronic tools, that the plan for anticoagulation management in the periprocedural period was discussed with the patient and with the clinician responsible for managing the patient's anticoagulation. Elements of the plan should include the following: discontinuation, resumption, and, if applicable, bridging, laboratory monitoring, and management of concomitant antithrombotic medications (such as antiplatelets and nonsteroidal anti-inflammatory drugs (NSAIDs)). An invasive or surgical procedure is defined as a procedure in which skin or mucous membranes and connective tissue are incised, or an instrument is introduced through a natural body orifice.

Validation

Implementation of a process to treat an anticoagulated patient undergoing a planned invasive procedure for which interruption in anticoagulation is anticipated, e.g. including patients taking vitamin K antagonists (warfarin)

Suggested Documentation

1) Documentation of a process to target specific oral anticoagulants (such as apixaban, dabigatran, and rivaroxaban), and heparins/low molecular weight heparins,  including through the use of electronic tools, that the plan for anticoagulation management in the periprocedural period was discussed with the patient and with the clinician responsible for managing the patient's anticoagulation; and  
2) The plan should include the following: discontinuation, resumption, and, if applicable, bridging, laboratory monitoring, and management of concomitant antithrombotic medications (such as antiplatelets and nonsteroidal anti-inflammatory drugs (NSAIDs)).  Note: an invasive or surgical procedure is defined as a procedure in which skin or mucous membranes and connective tissue are incised, or an instrument is introduced through a natural body orifice.

Register with MDinteractive